Disparities in cancer outcomes: Lessons learned from children with cancer

Pediatric Blood and Cancer

Volumn 56, Issue 6, 2011, Pages 994-1002

  Bhatia, Smita ^a  

^a City of Hope ^*  (United States)

Author keywords

Childhood cancer; Health disparities; Survival; Survivorship

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; HEMOGLOBIN; MERCAPTOPURINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ADVERSE OUTCOME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ATTITUDE TO HEALTH; AVASCULAR NECROSIS; BLAST CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOPULMONARY ARREST; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DELAYED DIAGNOSIS; DISEASE SEVERITY; DNA POLYMORPHISM; DRINKING BEHAVIOR; ENDOCRINE DISEASE; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; EVENT FREE SURVIVAL; GENE TRANSLOCATION; GENETIC POLYMORPHISM; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH DISPARITY; HEALTH INSURANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK BEHAVIOR; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMOBILIZATION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPH NODE; MULTIMODALITY CANCER THERAPY; NEUROBLASTOMA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE; REVIEW; RHABDOMYOSARCOMA; RISK FACTOR; SMOKING; THEORETICAL MODEL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS; ASIAN AMERICANS; CHILD; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH SERVICES ACCESSIBILITY; HISPANIC AMERICANS; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASMS; NEUROBLASTOMA; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RHABDOMYOSARCOMA; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952582252     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23078     Document Type: Review

References (60)

1. Freeman HP. Cancer in the socioeconomically disadvantaged. CA Cancer J Clin 1989; 39: 266-288.
2. Freeman HP. Cancer in the economically disadvantaged. Cancer 1989; 64: 324-334.
3. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved; Edited by M Alfred Haynes and Brian D Smedley. Washington (DC): The National Academies Press (US); 1999. ISBN-10: 0-309-07154-2.
4. Freeman HP. Commentary on the meaning of race in science and society. Cancer Epidemiol Biomarkers Prev 2003; 12: 232S-236S.
5. Tracking Healthy People 2010, in Service. UDoHaH (ed). Washington DC, US Government Printing Office; 2000.
6. Byes T, Mouchawar J, Marks J, et al. The American Cancer Society challenge goals. How far can cancer rates decline in the US by the year 2015? Cancer 1999; 86: 715-727.
7. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer 2008; 113: 2575-2596.
8. Kadan-Lottick N, Ness KK, Bhatia S, et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 2003; 290: 2008-2014.
9. Bhatia S, Sather HN, Heerema NA, et al. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 2002; 100: 1957-1964.
10. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood P-precursor acute lymphoblastic leukemia: A pediatric oncology group study. J Clin Oncol 2000; 18: 813-823.
11. Pui C-H, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003; 290: 2001-2007.
12. Pui C-H, Boyett JM, Hancock ML, et al. Outcome of treatment for childhood cancer in black compared with white children: The St. Jude Children's Research Hospital experience, 1962-1992. JAMA 1995; 273: 633-637.
13. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
14. Meshinchi S, Smith FO, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Curr Oncol Rep 2003; 5: 489-497.
15. Aplenc R, Alonzo TA, Gerbing RB, et al. Ethnicity and survival in childhood acute myeloid leukemia: A report from the Children's Oncology Group. Blood 2006; 108: 74-80.
16. Rubnitz JE, Lensing S, Razzouk BI, et al. Effect of race on outcome of white and black children with acute myeloid leukemia: The St. Jude Experience. Pediatr Blood Cancer 2007; 48: 10-15.
17. Percy CL, Smith MA, Linet M, et al. Lymphomas and reticuloendothelial neoplasms, In: Reis LA, Smith MA, Gurney JG, et al. editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda MD: National Cancer Institute; NIH publication 99-4649; 1999.
18. Metzger ML, Castellino SM, Hudson MM, et al. Effect of race on outcome of pediatric patients with Hodgkin's lymphoma. J Clin Oncol 2008; 26: 1282-1288.
19. Baker KS, Anderson JR, Lobe TE, et al. Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 2002; 20: 4428-4433.
20. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369: 2106-2120.
21. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2009; 27: 289-297.
22. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group Study. J Clin Oncol 2000; 18: 1260-1268.
23. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005; 23: 8819-8827.
24. De Bernardi B, Gerrard M, Boni L, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27: 1034-1040.
25. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 1007-1013.
26. Henderson TO, Bhatia S, Pinto N, et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: A Children's Oncology Group (COG) Study. J Clin Oncol 2011; 29: 76-82.
27. Barnholtz-Sloan JS, Severson RK, Stanton B, et al. Pediatric brain tumors in non-Hispanics, Hispanics, African-Americans and Asians: Differences in survival after diagnosis. Cancer Causes Control 2005; 16: 587-592.
28. Kaufman JS, Cooper RS. Considerations for use of racial/ethnic classification in etiologic research. Am J Epidemiol 2001; 154: 291-298.
29. Pappas G, Queen S, Hadden W, et al. The increasing disparity in mortality between socioeconomic groups in the United States, 1960 to 1986. N Engl J Med 1993; 324: 103-109.
30. Dang-Tan T, Franco EL. Diagnosis delays in childhood cancer. A review. Cancer 2007; 110: 703-713.
31. Stiller CA. Centralization of treatment and survival rates for cancer. Arch Dis Child 1988; 63: 23-30.
32. Stiller CA, Draper GJ. Treatment center size, entry to trials and survival in acute lymphoblastic leukemia. Arch Dis Child 1989; 64: 657-661.
33. Liu L, Krailo M, Reaman GH, et al. Childhood cancer patients' access to cooperative group cancer programs: A population-based study. Cancer 2003; 97: 1339-1345.
34. Lund MJ, Eliason MT, Haight AE, et al. Racial/ethnic diversity in Children's Oncology Group trials. Cancer 2009; 115: 3808-3816.
35. Aldrich MC, Zhang LP, Weimels JL, et al. Cytogenetics of Hispanic and white children with acute lymphoblastic leukemia in California. Cancer Epidemiol Biomarkers Prev 2006; 15: 578-581.
36. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
37. Lennard L, Lilleyman J, Loon JV, et al. Genetic variation in response to 6-mercaptopurine for childhood lymphoblastic leukemia. Lancet 1990; 336: 225-229.
38. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999; 93: 2817-2823.
39. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
40. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371-376.
41. Mcleod H, Lin J, Scott E, et al. Thiopurine methyltransferase activity in American white and American black subjects. Clin Pharmacol Ther 1994; 55: 15-20.
42. Mcleod H, Pritchard S, Githanga J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele-specificity in Caucasian and Kenyan subjects. Pharmacogenetics 1999; 9: 773-776.
43. Cooper SC, Ford LT, Berg JD, et al. Ethnic variation of thiopurine S-methyltransferase activity: A large, prospective population study. Pharmacogenomics 2008; 9: 303-309.
44. Stanulla M, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study. Blood 2000; 95: 1222-1228.
45. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
46. Koren G, Ferrazini G, Sulh H, et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 1990; 323: 17-21.
47. Betancourt JR, Carrillo JE, Green AR. Hypertension in multicultural and minority populations: Linking communication to compliance. Curr Hypertens Res 1999; 1: 482-488.
48. Singh N, Berman SM, Swindell S, et al. Adherence to human immunodeficiency virus-infected patients to anti-retroviral therapy. Clin Infect Dis 1999; 29: 824-830.
49. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: A possible indicator of non-compliance? Br J Cancer 1995; 72: 1004-1006.
50. Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: A problem of non-compliance? Br Med J 1993; 306: 1239-1240.
51. Lau RC, Matsui D, Greenberg M, et al. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol 1998; 30: 85-90.
52. Tebbi CK, Cummings KM, Zevon MA, et al. Compliance of pediatric and adolescent cancer patients. Cancer 1986; 58: 1179-1184.
53. Smith SD, Rosen D, Trueworthy RC, et al. A reliable method of evaluating drug compliance in children with cancer. Cancer 1979; 43: 169-173.
54. MacDougall LG, McElligot SE, Rose E, et al. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: Urinary assays as a measure of compliance. Ther Drug Monit 1992; 14: 371-375.
55. Welch JC, Lilleyman JS. Mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukemia. Cancer Chemother Pharmacol 1996; 38: 113-116.
56. Dibenedetto SP, Guardabasso V, Ragusa R, et al. 6-Mercaptopurine cumulative dose: A critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994; 11: 251-258.
57. Lennard L, Lilleyman JS. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 1994; 343: 1188-1190.
58. Kadan-Lottick N, Robison LL, Gurney JG, et al. Childhood cancer survivors' knowledge about their past diagnosis and treatment Childhood Cancer Survivor Study. JAMA 2002; 287: 1832-1839.
59. Castellino SM, Casillas J, Hudson MM, et al. Minority adult survivors if childhood cancer: A comparison of long-term outcomes, health care utilization, and health-related behaviors from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23: 6499-6507.
60. Armenian SH, Bhatia S. Chronic health conditions in childhood cancer survivors: Is it all treatment-related-or do genetics play a role? J Gen Intern Med 2009; 24: 395-400.